In 2002, Dr Thomas Pickering and our group introduced the term masked hypertension (MHT) 1 to describe individuals with normal clinic blood pressure (CBP) levels (<140/90 mm Hg) and ambulatory hypertension (awake ≥135/85 mm Hg). MHT is associated with increased left ventricular (LV) mass, 2 a marker of cardiovascular end-organ damage, and an increased risk of cardiovascular disease (CVD) events, that is significantly more than in sustained normotension (clinic and ambulatory normotension). [3][4][5][6][7] The confluence of increased CVD risk, a failure to be diagnosed by the conventional approach of blood pressure measurement in the clinic setting, and relatively high prevalence 8-11 makes MHT a public health concern.Epidemiologic studies have shown that CBP in the prehypertension (PHT) range (i.e., mean systolic blood pressure (SBP) 120-139 mm Hg or mean diastolic blood pressure (DBP) 80-89 mm Hg) confer an increased CVD risk. 12 PHT is associated with higher levels of LV mass 13 and also a higher risk of CVD events, 12 compared to optimal blood pressure levels (<120/80 mm Hg).Recent evidence suggests that CBP levels are significantly higher among individuals with MHT compared to individuals with sustained normotension, 9 despite both groups having CBP levels in the normal range (<140/90 mm Hg). These findings suggest that the prevalence of PHT may be disproportionally higher in MHT than in sustained normotension, or alternatively that the prevalence of MHT may be higher in PHT than in those with optimal CBP. These hypotheses have not been directly examined in previous studies, particularly when out-of-office blood pressure is determined by an ambulatory blood pressure (ABP) monitoring. Furthermore, the relative contributions of MHT and PHT to CVD risk are also unclear. The primary aim of this study was to evaluate the
BackgroundMasked hypertension (MHT) and prehypertension (PHT) are both associated with an increase in cardiovascular disease (CVD) risk, relative to sustained normotension. This study examined the diagnostic overlap between MHT and PHT, and their interrelationships with left ventricular (LV) mass index (LVMI), a marker of cardiovascular end-organ damage.